Insmed to Present at the 34th Annual J.P. Morgan Healthcare Conference
05 Janvier 2016 - 2:00PM
Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical
company focused on the unmet needs of patients with rare diseases,
today reported that company management will participate at the 34th
Annual J.P. Morgan Healthcare Conference on January 11-14, 2016 in
San Francisco. Will Lewis, president and chief executive
officer of Insmed, will deliver a corporate overview on Wednesday,
January 13th at 9:00 AM PT.
Mr. Lewis’ presentation will be webcast live and can be accessed
by visiting the investor relations section of the company’s website
at www.insmed.com. The webcast will be archived for a period of 90
days following the live webcast.
About Insmed
Insmed Incorporated is a global biopharmaceutical company
focused on the unmet needs of patients with rare diseases. The
company is advancing a global phase 3 clinical study of ARIKAYCE™
(liposomal amikacin for inhalation) in nontuberculous mycobacteria
(NTM) lung disease, a rare and often chronic infection that is
capable of causing irreversible lung damage and can be fatal when
left untreated. There are currently no products indicated for the
treatment of NTM lung disease in the United States or European
Union (EU). In the EU, the company has filed a marketing
authorization application seeking approval of ARIKAYCE for use in
patients with NTM lung disease. Insmed’s earlier-stage pipeline
includes INS1009, a nebulized prodrug formulation of treprostinil
that the company is developing for the treatment of pulmonary
arterial hypertension (PAH), a chronic, life-threatening disorder
characterized by abnormally high blood pressure in the arteries
between the heart and lungs. To complement its internal research,
Insmed actively seeks in-licensing opportunities for a broad range
of rare diseases. For more information, visit
www.insmed.com.
“Insmed” and “ARIKAYCE” are the company's trademarks. All other
trademarks, trade names or service marks appearing in this press
release are the property of their respective owners.
Insmed Incorporated:
Susan Mesco
Head of Investor Relations
susan.mesco@insmed.com
908-947-4326
Insmed (NASDAQ:INSM)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
Insmed (NASDAQ:INSM)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024